QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans (Q56447939)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

title

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

12

B S Graham

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

11

R Belshe

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

10

G J Gorse

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

5

K Weinhold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

2

M J McElrath

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

T G Evans

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

T Matthews

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

D Montefiori

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M Wolff

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M C Keefer

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

L Corey

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

P W Spearman

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

D Schwartz

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M J Mulligan

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

P Goepfert

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

P Fast

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

P Berman

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

M Powell

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

D Francis

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

NIAID AIDS Vaccine Evaluation Group

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

language of work or name

English

0 references

publication date

1 February 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

15-16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

2080-2091

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

Paracrine cytokine adjuvants in cancer immunotherapy

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

QS-21: a water-soluble triterpene glycoside adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Immunogenicity and toxicity testing of an experimental HIV-1 vaccine in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Iscoms Containing PurifiedQuillajaSaponins Upregulate both Th1-like and Th2-like Immune Responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Effect of adjuvants on immunogenicity of MN recombinant glycoprotein 120 in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Induction of antigen-specific killer T lymphocyte responses using subunit SIVmac251 gag and env vaccines containing QS-21 saponin adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

AIDSVAX (MN) in Bangkok injecting drug users: a report on safety and immunogenicity, including macrophage-tropic virus neutralization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Detection of intracellular antigen-specific cytokines in human T cell populations.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Human rabies in India: epidemiological features, management and current methods of prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Intradermal Hepatitis B Vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Low-dose intradermal and intramuscular vaccination against hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

Accessory cell requirements for saponin adjuvant-induced class I MHC antigen-restricted cytotoxic T-lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900415-1

7 January 2021

10.1016/S0264-410X(00)00415-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11228380%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference